Eli Lilly and Company (LLY) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,941,207 shares of the company’s stock after buying an additional 114,913 shares during the quarter. Dimensional Fund Advisors LP owned about 0.18% of Eli Lilly and worth $159,768,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after buying an additional 1,610,885 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after buying an additional 1,323,259 shares during the last quarter. State Street Corp grew its holdings in shares of Eli Lilly and by 1.6% during the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after buying an additional 651,424 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Eli Lilly and by 8.4% during the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC grew its holdings in shares of Eli Lilly and by 2.8% during the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after buying an additional 237,619 shares during the last quarter. 75.48% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently weighed in on LLY shares. TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Berenberg Bank reissued a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Jefferies Group LLC reissued a “buy” rating and set a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Piper Jaffray Companies reissued a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Finally, Cowen and Company reissued a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. Eli Lilly and has an average rating of “Hold” and a consensus target price of $89.76.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the company’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The disclosure for this sale can be found here. In the last quarter, insiders sold 772,003 shares of company stock valued at $64,837,441. Insiders own 0.20% of the company’s stock.

Eli Lilly and Company (NYSE LLY) opened at $82.19 on Thursday. The firm has a market cap of $90,829.33, a PE ratio of 20.17, a price-to-earnings-growth ratio of 1.82 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $64.18 and a 1 year high of $89.09. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.88 earnings per share. sell-side analysts expect that Eli Lilly and Company will post 4.22 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.

ILLEGAL ACTIVITY NOTICE: This report was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.themarketsdaily.com/2017/11/16/eli-lilly-and-company-lly-shares-bought-by-dimensional-fund-advisors-lp.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply